(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 4.37% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Johnson & Johnson's revenue in 2025 is $92,149,000,000.On average, 27 Wall Street analysts forecast JNJ's revenue for 2025 to be $228,136,153,208,380, with the lowest JNJ revenue forecast at $220,570,966,588,100, and the highest JNJ revenue forecast at $237,920,300,617,602. On average, 27 Wall Street analysts forecast JNJ's revenue for 2026 to be $240,300,684,178,378, with the lowest JNJ revenue forecast at $231,909,109,338,112, and the highest JNJ revenue forecast at $253,515,667,812,848.
In 2027, JNJ is forecast to generate $252,373,661,934,500 in revenue, with the lowest revenue forecast at $238,421,433,998,818 and the highest revenue forecast at $268,855,649,727,282.